HIGHLIGHTS
- who: Xuezhi Zhuo and colleagues from the Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken, Copenhagen, Denmark have published the research: A Comparative Study between a Protein Based Amorphous Formulation and Other Dissolution Rate Enhancing Approaches: A Case Study with Rifaximin, in the Journal: Pharmaceutics 2023, 126 of /2023/
- what: In this study the feasibility of the whey u03b2-lactoglobulin (BLG) as a co-former in ASDs was compared to the more traditional ASD co-formers well as to a nanocrystalline formulation.
- how: The collected data were analyzed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.